What's Happening?
Kyverna Therapeutics is advancing its CAR T-cell therapy, mivocabtagene autoleucel (miv-cel), towards market approval for stiff person syndrome (SPS), a rare autoimmune neurological disease. This progress
comes as competitors Novartis and Bristol Myers Squibb (BMS) have paused their autoimmune CAR T trials due to significant safety concerns, including patient deaths and inflammatory events. Kyverna recently reported positive one-year durability data from its Phase 2 KYSA-8 trial, showing miv-cel improved mobility and leg function in 26 SPS patients with a solid safety profile, notably without high-grade cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or immune effector cell-associated hemophagocytic lymphohistiocytosis–like syndrome (IEC-HS). Novartis's rap-cel was linked to three patient deaths from IEC-HS, while BMS observed 'transient and reversible inflammatory events' with its zolacabtagene autoleucel (zola-cel). Kyverna attributes miv-cel's safety to its established manufacturing process and a unique, fully human CD28 co-stimulatory domain designed for safety.
Why It's Important?
The potential approval of Kyverna's miv-cel would mark a significant milestone as the first CAR T therapy for an autoimmune condition, opening a new therapeutic avenue for diseases like SPS, which can be severely debilitating. The contrasting safety profiles among CAR T developers highlight the critical challenge of balancing efficacy with safety, especially when moving from oncology (where the risk-benefit ratio for life-threatening cancers is different) to autoimmune diseases, which are typically chronic rather than immediately fatal. Analysts have expressed caution regarding the broader application of CAR T in autoimmune conditions due to these safety setbacks. However, Kyverna's success could reignite enthusiasm and demonstrate that with careful design and manufacturing, CAR T therapies can be safely and effectively applied to autoimmune disorders, potentially transforming the lives of millions of patients who currently have limited treatment options. The market for autoimmune CAR T therapies is considered massive, potentially reaching millions of patients compared to hundreds of thousands in oncology.
What's Next?
Kyverna Therapeutics is on track to complete a rolling biologics license application (BLA) for miv-cel in SPS by the end of the year. This submission will be a critical step towards potential FDA approval. Meanwhile, Novartis and BMS will likely continue to investigate the safety issues with their respective CAR T candidates and adjust their trial protocols or manufacturing processes. The industry will be closely watching Kyverna's regulatory journey, as its success could set a precedent for future CAR T therapies in autoimmune diseases. Further research will also focus on understanding the specific mechanisms behind the differing safety profiles of various CAR T constructs and manufacturing methods to ensure safer development across the field. The broader implications for patient access and reimbursement for these highly specialized and potentially expensive therapies will also be a key area of focus.
Beyond the Headlines
This situation underscores the complex and rapidly evolving landscape of cell and gene therapies. The distinction between different CAR T constructs and manufacturing processes, as emphasized by industry experts, is crucial; not all cell therapies are created equal. The challenges faced by Novartis and BMS highlight the need for rigorous safety monitoring and a deep understanding of immune responses when deploying potent immunotherapies. This also brings to the forefront the ethical considerations of using high-risk therapies for non-fatal, albeit debilitating, conditions. The success of Kyverna could encourage more investment and research into tailored CAR T approaches for specific autoimmune diseases, potentially leading to a new era of personalized medicine for these conditions. Conversely, continued safety concerns could lead to stricter regulatory scrutiny and a more cautious approach to expanding CAR T applications beyond oncology.
